Learn Before
Concept
Camostat mesilate and Nafamostat
- Brand name: Fusan (nafamostat) and Foypan (camostat) (Japan)
- Indication: treatment of chronic pancreatitis and postoperative reflux of stomach acid back up into the esophagus
- Class: Serine protease inhibitors
- Mechanism: Camostat mesilate inhibits the enzymatic activity of TMPRSS2, a protease that divides the S2 subunit of the viral S protein of SARS-CoV-2 and is thus essential for cell entry of the virus. Nafamostat inhibits S protein initiated membrane fusion by targeting MERS-CoV and thus it may inhibit the coronavirus from entering the cell.
- Common AEs: Skin rashes, itching, GI events (nausea, abdominal pain) and changes in liver enzymes
- Drug-Drug Interactions: N/A
- Safety and Efficacy: The drugs seem well tolerated and can be used alone or in combination with other antivirals. Nafamostat significantly decreased S protein initiated membrane fusion between the virus and cell at low concentrations.
0
1
Updated 2021-05-01
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences